Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.

O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM.

BMC Cancer. 2013 Apr 2;13:175. doi: 10.1186/1471-2407-13-175.

2.

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM.

BMC Cancer. 2010 Nov 23;10:639. doi: 10.1186/1471-2407-10-639.

3.

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C.

J Pathol. 2012 Jan;226(1):97-107. doi: 10.1002/path.2976. Epub 2011 Sep 26.

PMID:
21953021
4.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

5.

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.

Jögi A, Brennan DJ, Rydén L, Magnusson K, Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, Pontén F, Jirström K.

Mod Pathol. 2009 Dec;22(12):1564-74. doi: 10.1038/modpathol.2009.124. Epub 2009 Sep 4.

6.

Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro.

Lanigan F, Gremel G, Hughes R, Brennan DJ, Martin F, Jirström K, Gallagher WM.

Breast Cancer Res. 2010;12(4):R59. doi: 10.1186/bcr2621. Epub 2010 Aug 3.

7.

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C.

Br J Cancer. 2012 May 22;106(11):1798-806. doi: 10.1038/bjc.2012.167. Epub 2012 Apr 26.

8.

P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.

Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA.

Mod Pathol. 2011 Jan;24(1):64-81. doi: 10.1038/modpathol.2010.189. Epub 2010 Sep 17.

9.

Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.

Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, Mertens PR.

BMC Cancer. 2009 Nov 24;9:410. doi: 10.1186/1471-2407-9-410.

10.

Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.

Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL.

Cancer. 2012 Oct 1;118(19):4660-9. doi: 10.1002/cncr.27453. Epub 2012 Feb 22.

11.

miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.

Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG, Gallagher WM, O'Connor DP.

Clin Cancer Res. 2012 Dec 15;18(24):6702-13. doi: 10.1158/1078-0432.CCR-12-1420. Epub 2012 Oct 11.

12.

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.

Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, Nasser E, Capp A, Sutherland RL.

Br J Cancer. 2011 Jul 12;105(2):272-80. doi: 10.1038/bjc.2011.228. Epub 2011 Jun 28.

13.

Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O.

Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18.

PMID:
20020198
14.

Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.

Berdel B, Nieminen K, Soini Y, Tengström M, Malinen M, Kosma VM, Palvimo JJ, Mannermaa A.

BMC Cancer. 2012 Nov 14;12:516. doi: 10.1186/1471-2407-12-516.

15.

Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.

Zhou W, Jirström K, Johansson C, Amini RM, Blomqvist C, Agbaje O, Wärnberg F.

BMC Cancer. 2010 Nov 30;10:653. doi: 10.1186/1471-2407-10-653.

16.

Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors.

Yan Y, Penner CC, Skliris GP, Cooper C, Nugent Z, Blanchard A, Hamedani MK, Wang X, Myal Y, Murphy LC, Leygue E.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1637-47. doi: 10.1007/s00432-013-1485-2. Epub 2013 Aug 2.

PMID:
23907597
17.

Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray.

Möllerström E, Kovács A, Lövgren K, Nemes S, Delle U, Danielsson A, Parris T, Brennan DJ, Jirström K, Karlsson P, Helou K.

BMC Cancer. 2010 Jun 16;10:296. doi: 10.1186/1471-2407-10-296.

18.

Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.

Serce NB, Boesl A, Klaman I, von Serényi S, Noetzel E, Press MF, Dimmler A, Hartmann A, Sehouli J, Knuechel R, Beckmann MW, Fasching PA, Dahl E.

BMC Cancer. 2012 Dec 13;12:597. doi: 10.1186/1471-2407-12-597.

19.

Expression profiling of ion channel genes predicts clinical outcome in breast cancer.

Ko JH, Ko EA, Gu W, Lim I, Bang H, Zhou T.

Mol Cancer. 2013 Sep 22;12(1):106. doi: 10.1186/1476-4598-12-106.

20.

A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.

Meyer S, Fuchs TJ, Bosserhoff AK, Hofstädter F, Pauer A, Roth V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild PJ.

PLoS One. 2012;7(6):e38222. doi: 10.1371/journal.pone.0038222. Epub 2012 Jun 7.

Items per page

Supplemental Content

Write to the Help Desk